fda glp-1 shortage Shortages improve for Lilly's weight loss drugs, bumping sales forecast by $3bn Ozempic, Wegovy shortages prompt tech

Gentle on the stomach

This program will help you educate your patients on how to use the medication and how they can keep the weight off for good with lifestyle change.

Lilly narrows gap with Novo Nordisk in GLP-1 market as Q2 2024 sales figures show strong growth, but Ozempic remains the GLP-1 king.

Full Text: #Pharmacogenomics #GLP1 #Semaglutide #Tirzepatide #GWAS

The reason behind the drugs immense popularity is its effectiveness in managing weight, a phenomenonenthusiastically promoted by social media influencers.Wegovy is a glucagon-like peptide-1 receptor agonist (also known as GLP-1 receptor agonist or GLP-1 RA), which bagged US Food and Drug Administrations approval as a treatment for obesity in June 2021